Treats Major Depressive Disorder (MDD). ANDA 203836, held by Ph Health. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 203836 (Fluoxetine Hydrochloride), held by Ph Health, was first approved by FDA on Aug 19, 2016, with 2 approved supplements and 0 published complete response letters.
Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adults and pediatric patients aged 7 to 17 years Acute and maintenance treatment of Bulimia Nervosa in adult patients Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients Indication Adult Pediatric MDD 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa 60 mg/day in am Panic Disorder 10 mg/day (initial dose) A lower or le…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2016 | Original application | Approved |
| Fluoxetine HydrochlorideEQ 10MG BASE · tablet;oral | Fluoxetine Hydrochloride | Rx |
| Fluoxetine HydrochlorideEQ 20MG BASE · tablet;oral | Fluoxetine Hydrochloride | Rx |
| Aug 18, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 21, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 19, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters